Volume | 69,546 |
|
|||||
News | - | ||||||
Day High | 36.57 | Low High |
|||||
Day Low | 35.79 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
35.95 | 35.79 | 36.57 | 35.84 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,666 | 69,546 | $ 36.30 | $ 2,524,348 | - | 20.83 - 40.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:14:48 | 3 | $ 36.46 | USD |
Collegium Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.16B | 31.96M | - | 566.77M | 48.16M | 1.51 | 24.16 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Collegium Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 34.65 | 36.57 | 34.24 | 35.45 | 420,878 | 1.77 | 5.11% |
1 Month | 38.54 | 40.49 | 34.24 | 36.83 | 342,364 | -2.12 | -5.50% |
3 Months | 33.44 | 40.95 | 31.34 | 36.76 | 430,274 | 2.98 | 8.91% |
6 Months | 21.88 | 40.95 | 20.95 | 32.58 | 419,101 | 14.54 | 66.45% |
1 Year | 22.70 | 40.95 | 20.83 | 28.43 | 362,394 | 13.72 | 60.44% |
3 Years | 23.36 | 40.95 | 14.04 | 23.67 | 333,748 | 13.06 | 55.91% |
5 Years | 14.57 | 40.95 | 10.01 | 21.63 | 368,602 | 21.85 | 149.97% |
Collegium Pharmaceutical Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |